BUND FINANCE › Stocks › RVMD
Revolution Medicines, Inc. (RVMD)
NASDAQ · Stock price, chart and technical analysis
Data from Financial Modeling Prep · Nov 18, 2026, 4:00 PM New York time · may be delayed
Key stats
Quick technical read
- Price is -17.07% below its 50-day average.
- It is -0.46% below its 200-day average (long-term downtrend).
- It sits at 58% of its 52-week range (0% = low, 100% = high).
This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it
Fundamentals Annual
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | US$29.4M | US$35.4M | US$11.6M | US$0 | US$0 |
| Net income | −US$187.1M | −US$248.7M | −US$436.4M | −US$600.1M | −US$1.1B |
| EPS (diluted) | -2.57 | -3.08 | -3.86 | -3.58 | -5.95 |
| Gross margin | 100.0% | 100.0% | 100.0% | — | — |
| Operating margin | -639.7% | -730.0% | -4,207.1% | — | — |
| Net margin | -636.6% | -703.0% | -3,768.3% | — | — |
| Free cash flow | −US$153.7M | −US$235.2M | −US$358.3M | −US$567.7M | −US$913.7M |
| Total debt | US$66.6M | US$64.2M | US$87.9M | US$135.8M | US$158.7M |
| Cash | US$108.5M | US$161.4M | US$696.1M | US$543.1M | US$383.7M |
Valuation: today, its history and its sector
| Today | 5-year average | Sector median (Healthcare) | |
|---|---|---|---|
| P/E | — | — | 27.1x |
| EV / EBITDA | — | — | 16.5x |
| Operating margin | -853.0% | — | 3.6% |
| Net margin | -946.8% | — | -0.0% |
| Debt / equity | 0.79 | — | 0.58 |
Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.
About Revolution Medicines, Inc.
Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic ar…
Other stocks on BUND FINANCE
Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice